|
Market Closed -
Nasdaq
00:00:00 15/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 18.18 USD | +1.62% |
|
-8.64% | +17.82% |
| 09-09 | Jade Biosciences, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 09:20 AM | |
| 09-04 | Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says | MT |
Company Valuation: Jade Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Market Cap 1 | 709.8 | 1,156 | - | - |
| Change | - | 62.88% | - | - |
| Enterprise Value (EV) 1 | 373.7 | 810.5 | 802.5 | 820.3 |
| Change | - | 116.9% | -0.99% | 2.22% |
| P/E | -4.84x | -6.23x | -6.34x | -6.39x |
| PBR | - | 4.23x | 9.08x | 5.04x |
| PEG | -0.2x | 0.74x | 3.62x | 7.44x |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | -3.61x | -3.46x | -3.41x |
| EV / EBIT | -3.29x | -3.81x | -3.39x | -3.14x |
| EV / FCF | -3.94x | -4.73x | -3.43x | -3.25x |
| FCF Yield | -25.4% | -21.2% | -29.2% | -30.8% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -3.19 | -2.92 | -2.869 | -2.845 |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | - | - | - |
| EBITDA 1 | - | -224.4 | -232.3 | -240.4 |
| EBIT 1 | -113.5 | -212.7 | -236.8 | -261.7 |
| Net income 1 | -127.4 | -204.2 | -231.1 | -258.9 |
| Net Debt 1 | -336.2 | -345.7 | -353.7 | -335.9 |
| Reference price 2 | 15.43 | 18.18 | 18.18 | 18.18 |
| Nbr of stocks (in thousands) | 46,004 | 63,597 | - | - |
| Announcement Date | 06/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.13x | - | -3.53x | - | 1.14B | |
| 31.04x | 5.6x | 16.76x | 1.05% | 45.48B | |
| -20.85x | 240.83x | -22.36x | -.--% | 43.68B | |
| 33.71x | 3.27x | 14.1x | -.--% | 43.09B | |
| 45.39x | 5.23x | 28.64x | -.--% | 39.4B | |
| 27.03x | 8.15x | 20.66x | 0.42% | 31.91B | |
| 33.41x | 5.47x | 24.85x | -.--% | 16.4B | |
| 23.57x | 2.06x | 8.94x | 1.13% | 14.24B | |
| 74.44x | 3.94x | 15.27x | -.--% | 13.28B | |
| Average | 26.85x | 34.32x | 11.48x | 0.33% | 27.62B | |
| Weighted average by Cap. | 26.03x | 46.68x | 11.72x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- JBIO Stock
- Valuation Jade Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
